StockWatch
·
HEALTHCARE GLOBAL ENTERPRISES LTD · QQ2 FY-2027 · THE CALL

13% growth, 55% PAT collapse; regulatory headwind looms

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsHCGHealthCare Global Enterprises Ltd09 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade C

Q2 delivered 13.1% growth, below claimed 16% on like-for-like basis. PAT miss of 55% YoY significant; management shifted to 'adjusted PAT' narrative, obscuring GAAP reality.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Revenue growth at 13.1% is mid-teens but softer than claimed (16% on adjusted basis). PAT crashed 55% due to regulatory provision (EPCG ₹116 Cr H1) and tax headwinds, masking underlying operational stability (EBITDA margin +84 bps). Regulatory trade margin caps kick Q3, adding near-term drag. Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.

₹731.8 Cr

Revenue · +13.1% YoY

₹9.3 Cr

Reported PAT · −55.2% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

16% Q2 revenue growth excluding Milann

MISS

13.1% YoY on GAAP reported basis (₹731.8 Cr)

EBITDA margin 19.7% with 17% growth

MET

EBITDA ₹142.5 Cr margin 19.5% consistent, delivery confirmed

Adjusted PAT 30% growth in H1

OVERSTATED

Q2 GAAP PAT ₹9.3 Cr down 55.2% YoY; H1 adjusted masks one-time charges

North Bengaluru ramp improving; target Q4 monthly EBITDA breakeven

Partial

Q1 loss ₹7.5 Cr, Q2 loss ₹6 Cr; trajectory reasonable, not yet breakeven

Earnings quality

What changed since the last call

Deltas vs. the prior call

Regulatory trade margin cap introduced

New

137 oncology drugs now capped at 30% margin; estimated mid-high single-digit EBITDA impact annually, effective Q3 onwards. Not in prior guidance.

Revenue growth guidance reaffirmed but delivered softer

Downgrade

Claim: 16% Q2 growth (like-for-like excl. Milann). Delivered: 13.1% GAAP reported YoY. 3pp miss on topline vs narrative.

North Bengaluru losses narrowing; Q4 breakeven target

Neutral

Q1 loss ₹7.5 Cr, Q2 loss ₹6 Cr. Management confident monthly EBITDA breakeven by Q4 FY27 (Jan 2027). Ramp on track but still diluting overall PAT.

The Q&A

Analysts pressed hard on price cap quantification, PAT decline, and growth deceleration. Management held firm on 'mid-teens' and deflected with 'adjusted' metrics. Q&A tone reflected measured confidence, not aggressive. North Bengaluru ramp defended as network synergy, not standalone. Q&A score: 6/10 (adequate, not transparent).

The exchanges that mattered

Price cap drug impact — Aditya Chheda, InCred Asset Management

Partial

Mid-to-high single digit percentage EBITDA impact annually. Effective Q3 (November). Multiple levers (volume, asset utilization, mix) to offset. No change to guidance.

North Bengaluru ramp — Devang Patel, Sameeksha Capital

Answered

On track to hit monthly EBITDA breakeven by Q4 FY27. Facility serves new micro-market, positive network synergy on KR Center. Ramp-up improving faster than prior hospitals.

Revenue growth guidance — Sumit Gupta, Antique Stock Broking

Dodged

Mid-teens guidance stands. Q2 inclusive of some headwinds (mix, regulation). Most clusters performing well; Gujarat deliberate pullback on low-margin payors. Expect gradual improvement.

EPCG provision impact — Aditya Chheda, InCred

Answered

Provision covers all export obligations. No further material provisions expected. Provision is retroactive; does not impact current cash flow.

Cash flow and OCF conversion — Devang Patel, Sameeksha Capital

Answered

Temporary: supplier credit terms extended (30 vs 90 days prior), ₹35 Cr AP Government subsidy timing, tax accrual increased. Normalized to ~54%. Expected to improve and revert closer to 80% as one-time items normalize.

Payor mix rationalization — Nitin Agarwal, DAM Capital

Answered

Conscious tradeoff. Non-institutional revenue grew 21% Q2 vs institutional 5%. Clinical talent, infrastructure, and marketing driving premium case mix. Gradual, not abrupt. Focus on sustainable margin expansion.

ARPP growth sustainability — Nitin Agarwal, DAM Capital

Partial

Combination of higher robotic surgeries, high-end radiation therapies, payroll mix shift. Guidance reaffirms ARPP growth in line with inflation (~single digit) going forward. Growth across clusters expected to improve over time.

MVT (Medical Value Travel) growth — Gopal Bhatt, Baroda BNP Paribas

Answered

FY26 ~3%, FY27 H1 ~4–5%, growing at 25% YoY. Geopolitical disturbance did impact, but HCG offsetting through improved screening and affordability messaging. Long-term structural tailwind on cancer incidence and quality care demand.

Guidance

Forward guidance and management's confidence

Mid-teens (13–19%) revenue growth FY27 maintained

Medium

Q2 delivered 13.1% (low end). Management reaffirmed guidance despite price cap headwind (Q3 effective). Conditional on volume resilience and mix improvement.

21–22% EBITDA margin target within 2 years; 24–25% by year 5

Medium

Current 19.7% stable. Path to 21–22% requires volume growth + operational efficiency + price cap offset. Ambitious given regulatory headwind introduced post-Q1 guidance.

₹520 bed expansion FY28–29

Medium

H1 capex ₹127.9 Cr noted; infrastructure and medical technology upgrades ongoing. Bed additions tracking on plan (25 in Q2, 146 H1).

Risks the call surfaced

Ranked by how much they should concern a holder

Regulatory price cap

High

137 oncology drugs (small subset of portfolio but including immunotherapy, high-margin segment) now capped at 30% margin. Estimated mid-to-high single-digit EBITDA impact on annualized basis; effective Q3 FY27.

North Bengaluru ramp-up

Medium

Hospital lost ₹7.5 Cr in Q1 FY27, ₹6 Cr in Q2. Path to monthly EBITDA breakeven by Q4 FY27 credible but execution-dependent. Any delay extends PAT drag.

PAT volatility from one-time charges

High

Q2 PAT collapsed 55% YoY (₹9.3 Cr) despite 13% revenue growth and stable EBITDA. EPCG provision (₹116 Cr H1), tax swing (₹30 Cr accrual vs ₹99.6 Cr deferred asset prior), and D&A burden responsible. Management's 'adjusted PAT' narrative (₹28.7 Cr H1, +30% growth) diverts from GAAP miss.

Revenue growth deceleration

Medium

Q2 GAAP reported revenue growth 13.1% YoY (₹731.8 Cr) vs management claim of 16% on like-for-like basis (excluding Milann divested June 2026). 3 percentage point gap indicates either lower underlying growth or mix headwinds.

Geopolitical headwinds on MVT

Low

MVT (Medical Value Travel) growing at 25% YoY but exposed to Middle East and Bangladesh geopolitical risks. Disruptions cited as partial offset to growth. Long-term tailwind but near-term visibility uncertain.

Management

Score 6/10. Moderately transparent. Management provided operational context and flagged regulatory headwind, but shifted to 'adjusted PAT' narrative to soften GAAP collapse. Disclosed one-time items (EPCG, tax swing) but minimized their materiality. Candid on payor rationalization strategy. Operational performance stable (EBITDA margin +84 bps) but revenue growth missed topline claim (13.1% vs 16% adjusted basis, 3pp gap). North Bengaluru ramp-up on trajectory but still loss-making. Bed capacity additions tracking plan (25 Q2, 146 H1). Prior guidance (mid-teens growth, 21–22% margin within 2yr) largely reaffirmed despite new regulatory headwind.

What to watch next
  • 1 · Q3 FY27 (Oct–Dec 2026)

    Trade margin cap on 137 oncology drugs effective; mid-high single-digit EBITDA headwind quantified

  • 2 · Q4 FY27 (Jan–Mar 2027)

    North Bengaluru target monthly EBITDA breakeven; validates ramp and visibility into FY28 profitability uplift

  • 3 · FY28–29

    ₹520 bed expansion (Kenya, Kolkata, Nagpur, Bengaluru); capacity growth and geographic diversification underway

Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.

Informational and educational content only. Not investment advice.